Redhill Biopharma Ltd. (RDHL) Expected to Post Quarterly Sales of $1.27 Million

Equities analysts expect Redhill Biopharma Ltd. (NASDAQ:RDHL) to announce $1.27 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Redhill Biopharma’s earnings, with the lowest sales estimate coming in at $900,000.00 and the highest estimate coming in at $1.64 million. The business is expected to issue its next earnings report on Monday, November 13th.

On average, analysts expect that Redhill Biopharma will report full year sales of $1.27 million for the current financial year, with estimates ranging from $500,000.00 to $4.69 million. For the next fiscal year, analysts forecast that the company will post sales of $47.25 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.

Several analysts recently weighed in on RDHL shares. UBS AG started coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating for the company. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Roth Capital set a $27.00 price objective on Redhill Biopharma and gave the stock a “buy” rating in a research report on Monday, July 31st. HC Wainwright set a $33.00 price objective on Redhill Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Seaport Global Securities started coverage on Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.35.

Shares of Redhill Biopharma (NASDAQ:RDHL) traded up 1.0057% during mid-day trading on Thursday, hitting $8.7976. The stock had a trading volume of 54,018 shares. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.22. The stock’s 50-day moving average price is $9.05 and its 200 day moving average price is $9.26. The company’s market capitalization is $150.99 million.

A number of institutional investors and hedge funds have recently modified their holdings of RDHL. Renaissance Technologies LLC increased its holdings in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. Jane Street Group LLC acquired a new position in Redhill Biopharma in the 1st quarter worth about $276,000. Bank of New York Mellon Corp acquired a new position in Redhill Biopharma in the 1st quarter worth about $101,000. Family Management Corp increased its holdings in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in Redhill Biopharma by 36.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 6,172 shares in the last quarter. 10.99% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/19/redhill-biopharma-ltd-rdhl-expected-to-post-quarterly-sales-of-1-27-million.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks resea

On average, analysts expect that Redhill Biopharma will report full year sales of $1.27 million for the current financial year, with estimates ranging from $500,000.00 to $4.69 million. For the next fiscal year, analysts forecast that the company will post sales of $47.25 million per share, with estimates ranging from $11.01 million to $113.90 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last announced its earnings results on Tuesday, July 25th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.02). The firm had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million.

Several analysts recently weighed in on RDHL shares. UBS AG started coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They set a “reduce” rating for the company. Zacks Investment Research upgraded Redhill Biopharma from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Roth Capital set a $27.00 price objective on Redhill Biopharma and gave the stock a “buy” rating in a research report on Monday, July 31st. HC Wainwright set a $33.00 price objective on Redhill Biopharma and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Seaport Global Securities started coverage on Redhill Biopharma in a research report on Friday, October 6th. They set a “buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $23.35.

Shares of Redhill Biopharma (NASDAQ:RDHL) traded up 1.0057% during mid-day trading on Thursday, hitting $8.7976. The stock had a trading volume of 54,018 shares. Redhill Biopharma has a 1-year low of $8.16 and a 1-year high of $14.22. The stock’s 50-day moving average price is $9.05 and its 200 day moving average price is $9.26. The company’s market capitalization is $150.99 million.

A number of institutional investors and hedge funds have recently modified their holdings of RDHL. Renaissance Technologies LLC increased its holdings in Redhill Biopharma by 144.1% in the 1st quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock worth $595,000 after purchasing an additional 36,600 shares in the last quarter. Jane Street Group LLC acquired a new position in Redhill Biopharma in the 1st quarter worth about $276,000. Bank of New York Mellon Corp acquired a new position in Redhill Biopharma in the 1st quarter worth about $101,000. Family Management Corp increased its holdings in Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp now owns 25,750 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 8,750 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in Redhill Biopharma by 36.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 23,069 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 6,172 shares in the last quarter. 10.99% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/10/19/redhill-biopharma-ltd-rdhl-expected-to-post-quarterly-sales-of-1-27-million.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply